GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guangdong Marubi Biotechnology Co 603983.SS · CNY

Consumer Staples · Shanghai · 🇨🇳 China

Compare

23.89

-1.36%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥3.46bn

FY2016FY2025

Net income

CN¥247.2m

FY2016FY2025

Free cash flow

CN¥68.6m

FY2016FY2025

Shareholders' equity

CN¥3.33bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥3.46bnCN¥2.97bnCN¥2.23bnCN¥1.73bnCN¥1.79bnCN¥1.74bnCN¥1.80bnCN¥1.58bnCN¥1.35bnCN¥1.21bn
Gross profitCN¥2.57bnCN¥2.18bnCN¥1.56bnCN¥1.17bnCN¥1.13bnCN¥1.15bnCN¥1.22bnCN¥1.07bnCN¥917.4mCN¥817.5m
Research and developmentCN¥85.4mCN¥73.5mCN¥62.3mCN¥52.9mCN¥50.5mCN¥50.2mCN¥44.9mCN¥33.8mCN¥28.3mCN¥24.8m
Operating incomeCN¥253.9mCN¥380.9mCN¥319.3mCN¥207.3mCN¥299.0mCN¥572.5mCN¥612.6mCN¥484.2mCN¥366.1mCN¥260.3m
Net incomeCN¥247.2mCN¥341.6mCN¥259.4mCN¥174.2mCN¥247.9mCN¥464.4mCN¥514.9mCN¥415.3mCN¥311.9mCN¥232.2m
Diluted earnings per share0.620.850.650.430.651.131.302.230.780.58

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.61bnCN¥5.06bnCN¥4.45bnCN¥4.09bnCN¥3.76bnCN¥3.80bnCN¥3.44bnCN¥2.12bnCN¥1.60bnCN¥1.48bn
Cash and short-term investments—CN¥2.43bnCN¥2.12bnCN¥1.51bnCN¥1.54bnCN¥2.49bnCN¥2.90bnCN¥1.56bnCN¥1.10bnCN¥941.5m
Total liabilitiesCN¥1.22bnCN¥1.62bnCN¥1.04bnCN¥838.6mCN¥603.2mCN¥794.4mCN¥766.4mCN¥735.0mCN¥643.0mCN¥647.8m
Debt—CN¥791.6mCN¥255.5mCN¥270.4mCN¥19.5mCN¥106.7m———CN¥20.6m
Shareholders' equityCN¥3.33bnCN¥3.38bnCN¥3.35bnCN¥3.19bnCN¥3.08bnCN¥2.98bnCN¥2.67bnCN¥1.38bnCN¥960.0mCN¥828.1m
Shares outstanding401m401m401m401m382m411m395m186m401m401m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥273.9mCN¥300.5mCN¥338.0mCN¥48.4m−CN¥7.5mCN¥362.3mCN¥465.5mCN¥516.7mCN¥356.2mCN¥213.3m
Capital spending−CN¥205.2m−CN¥316.4m−CN¥254.0m−CN¥110.9m−CN¥117.1m−CN¥748.9m−CN¥6.4m−CN¥11.3m−CN¥6.4m−CN¥6.6m
Free cash flowCN¥68.6m−CN¥15.8mCN¥84.0m−CN¥62.5m−CN¥124.6m−CN¥386.6mCN¥459.1mCN¥505.3mCN¥349.8mCN¥206.7m
Dividends paid−CN¥300.9m−CN¥313.2m−CN¥106.1m−CN¥76.2m−CN¥141.9m−CN¥156.8m−CN¥156.8m−CN¥156.8m−CN¥180.0m−CN¥120.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥781.8mCN¥881.3mCN¥1.01bnCN¥681.2mCN¥922.5mCN¥846.6mCN¥1.02bnCN¥600.0m
Gross profitCN¥574.2mCN¥650.6mCN¥734.1mCN¥515.8mCN¥674.6mCN¥643.9mCN¥719.5mCN¥452.7m
Operating incomeCN¥2.9mCN¥118.3mCN¥9.2mCN¥12.2mCN¥75.1mCN¥166.0mCN¥98.8mCN¥57.5m
Net incomeCN¥54.5mCN¥101.0mCN¥3.3mCN¥58.2mCN¥50.7mCN¥135.0mCN¥102.8mCN¥62.3m
Diluted earnings per share0.140.250.010.150.130.340.260.16
Cash from operations———CN¥43.0mCN¥143.0m−CN¥26.0mCN¥234.0mCN¥10.0m
Capital spending−CN¥26.0m−CN¥77.0m−CN¥28.0m−CN¥56.0m−CN¥51.0m−CN¥69.0m−CN¥55.0m−CN¥87.0m
Free cash flow———−CN¥13.0mCN¥92.0m−CN¥95.0mCN¥179.0m−CN¥77.0m
Total assetsCN¥4.63bnCN¥4.69bnCN¥4.61bnCN¥4.85bnCN¥4.77bnCN¥4.78bnCN¥5.06bnCN¥4.44bn
Cash and short-term investments———CN¥2.00bnCN¥2.00bnCN¥2.08bnCN¥2.43bnCN¥1.85bn
Debt———CN¥574.0mCN¥548.0mCN¥510.0mCN¥790.1mCN¥248.8m
Shareholders' equityCN¥3.38bnCN¥3.43bnCN¥3.33bnCN¥3.32bnCN¥3.37bnCN¥3.52bnCN¥3.38bnCN¥3.38bn

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2016FY2015
Gross margin74.3%73.3%70.1%67.8%63.4%65.9%——
Operating margin7.3%12.8%14.3%12.0%16.7%32.8%——
Net margin7.1%11.5%11.7%10.1%13.9%26.6%——
Return on equity7.4%10.1%7.8%5.5%8.0%15.6%——
Return on assets5.4%6.7%5.8%4.3%6.6%12.2%——
Free cash flow yield3.9%5.0%4.8%1.3%0.9%8.8%——
Revenue growth16.5%33.4%28.5%-3.1%2.4%-3.1%——
Earnings growth-27.6%31.7%48.9%-29.7%-46.6%-9.8%——
Current ratio1.87x1.85x2.50x3.35x3.43x3.41x——
Debt to equity—0.23x0.03x0.08x—0.04x0.02x0.02x
Equity ratio72.2%66.8%75.2%77.9%82.0%78.5%——
Interest coverage77.34x36.81x45.35x58.85x292.06x504.71x——
R&D as a share of sales2.5%2.5%2.8%3.1%2.8%2.9%——
Buybacks as a share of market value0.0%0.0%0.0%-4.9%6.9%-4.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue25.9%14.7%11.2%
Operating income7.0%-15.0%-2.1%
Net income12.4%-11.8%-1.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin73.8%72.0%70.1%69.4%
Operating margin9.9%11.2%14.6%19.3%
Net margin9.2%9.8%12.5%16.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings53.837.939.177.749.146.246.1
Price to sales3.84.44.57.86.812.313.2

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 16 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year0.250.750.770.250.190.350.39

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.